As the SARS-CoV-2 pandemic continues to cause concerns, with new variants spreading worldwide, it is now widely recognised that there must be a move beyond a ‘test & trace’ only approach.
World leaders and health institutions aim to achieve high immunity rates among the population, facing the unprecedented challenge of a worldwide vaccination campaign against an emerging virus, for which no vaccine existed until a year ago.
"Alongside our genetic tests to detect SARS-CoV-2 anywhere, and at any time, we knew that we had to put our knowledge at the service of vaccination campaigns even further, leveraging the versatility of our AI platform to deliver a new kind of immunology test," said Stefano Lo Priore, founder and CEO at Hyris, a global biotechnology company renowned for its innovative and inclusive approach to genetic analysis. Hyris offers a wide range of solutions to support the fight against COVID-19 worldwide. Several medical professionals and decision-makers have already made use of the Hyris System to detect the presence of all the main Variants of Concern.
As a key part of a long-term strategy to fight COVID-19, Hyris continues to support immunology research, with the presentation of its new test to detect the body's T-cell immune response to SARS-CoV-2 recently at ‘A-WISH’, Alicante-Winter Immunology Symposium in Health.
Organised by the Spanish Society of Immunology (SEI) and the University of Alicante (UA), the A-WISH symposium promoted the advancement of the study of immunology, infectious diseases and vaccinology, as well as life and health sciences. This first edition specifically aimed to address strategies for the COVID-19 response and pandemic preparedness, the development of the vaccines against SARS-CoV-2, and the immunological response to infection and different COVID-19 vaccines.
